Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations

被引:122
作者
Olesen, OV [1 ]
Linnet, K [1 ]
机构
[1] Univ Risskov, Hosp Psychiat, Lab Clin Biochem, Dept Biol Psychiat, DK-8240 Risskov, Denmark
关键词
D O I
10.1177/00912700122010717
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM). In contrast to previous studies, the authors focused on a relatively low hepatic concentration level, 5 muM, to assess the conditions at a therapeutically relevant hepatic concentration level of clozapine. The optimal concentrations of specific inhibitors were initially established using cDNA-expressed CYP isoforms. The mean contributions of CYPs 1A2, 2C1 9, 3A4, 2C9, and 2D6 amounted to 30%, 24%, 22%, 12%, and 6%, respectively, with regard to the total HLM-mediated N-demethylation. Thus, the present in vitro study on clozapine N-demethylation suggests that CYP1A2 is the most important form at low concentrations, which is in agreement with clinical findings. CYP2C19 is also of considerable importance, while the roles of CYP2C9 and 2D6 are more modest. CYP3A4 attained a dominating role with an average contribution of 37% at a high clozapine concentration (50 muM). The rate of other metabolic routes mediated by CYP2D6 only corresponded to about one fifth of the CYP2D6 catalyzed N-demethylation rate. (C) 2001 the American College of Clinical Pharmacology.
引用
收藏
页码:823 / 832
页数:10
相关论文
共 40 条
[1]   CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].
ALVIR, JMJ ;
LIEBERMAN, JA ;
SAFFERMAN, AZ ;
SCHWIMMER, JL ;
SCHAAF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167
[2]  
[Anonymous], 1995, DISPOSITION TOXIC DR
[3]  
BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746
[4]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[5]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[6]  
Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
[7]   Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients [J].
Carrillo, JA ;
Herraiz, AG ;
Ramos, SI ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (04) :311-316
[8]   In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine [J].
Chang, WH ;
Augustin, B ;
Lane, HY ;
ZumBrunnen, T ;
Liu, HC ;
Kazmi, Y ;
Jann, MW .
PSYCHOPHARMACOLOGY, 1999, 145 (01) :91-98
[9]   Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients [J].
Chang, WH ;
Lin, SK ;
Lane, HY ;
Wei, FC ;
Hu, WH ;
Lam, YWF ;
Jann, MW .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1998, 22 (05) :723-739
[10]   CLINICAL PHARMACOKINETICS OF CLOZAPINE IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
CHENG, YF ;
LUNDBERG, T ;
BONDESSON, U ;
LINDSTROM, L ;
GABRIELSSON, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :445-449